This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Assessing the ET-400 PDUFA Milestone and Market Impact for Pediatric Adrenal Insufficiency

Ticker(s): ETON

Who's the expert?

A pediatric endocrinologist, regulatory affairs specialist, or pharmaceutical commercialization strategist with direct experience in adrenal disorders, compounded therapies, and FDA 505(b)(2) approval pathways.

Interview Questions
Q1.

Eton stated there are no outstanding IRs or deficiencies for ET-400 ahead of its May 28 PDUFA date. What does this imply in terms of FDA likelihood for timely approval and how common is this level of clarity in late-stage filings?

Added By: slingshot_insights
Q2.

How does ET-400 compare pharmacologically and logistically with compounded oral suspensions, especially considering the FDA's prohibition against compounded copies once an approved alternative exists?

Added By: slingshot_insights
Q3.

Eton positions ET-400 as complementary to Alkindi Sprinkle. How do these two products differ in real-world clinical use, and what does this mean for payer coverage and prescriber preference?

Added By: slingshot_insights
Q4.

With 50% of patients still using compounded or homemade hydrocortisone, what percentage of that market do you believe ET-400 can realistically convert within its first 12–18 months post-approval?

Added By: slingshot_insights
Q5.

Eton claims commercial launch will occur within a week of approval. What operational steps need to be in place to ensure success in such a fast turnaround, especially in ultra-rare markets?

Added By: slingshot_insights
Q6.

Assuming ET-400 launches in Q3 2025, how pivotal is this product for reaching Eton’s $80M end-of-year revenue run rate, especially given the projected $50M+ annual sales potential for ET-400 and Alkindi combined?

Added By: slingshot_insights
Q7.

What are some unique formulation or delivery challenges that ET-400 solves compared to traditional steroid therapies in pediatric adrenal insufficiency?

Added By: slingshot_insights
Q8.

Upon FDA approval, how likely is it that ET-400 could influence pediatric endocrinology guidelines or shift clinical preference away from non-approved compounded alternatives?

Added By: slingshot_insights

Are You Interested In These Questions?

Slingshot Insights Explained
208Days Left to Join Project

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.